FTY720 mediates activation suppression and G 0/G 1 cell cycle arrest in a concanavalin A-induced mouse lymphocyte pan-activation model

Inflammation Research

Volumn 61, Issue 6, 2012, Pages 623-634

  Zeng, Xiangfeng ^a   Wang, Tong ^a   Zhu, Cairong ^b   Ye, Yanxia ^a   Song, Bing ^a   Lai, Xinqiang ^a   Zeng, Yaoying ^a  

^a JINAN UNIVERSITY   (China)

^b GUANGZHOU WOMEN AND CHILDREN S MEDICAL CENTER   (China)

Author keywords

Ca 2+; ConA; FTY720; G 0 G 1; T cell

Indexed keywords

CALCIUM ION; CD69 ANTIGEN; CONCANAVALIN A; FINGOLIMOD; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MITOGENESIS; MOUSE; NONHUMAN; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CELL SURVIVAL; CONCANAVALIN A; DOWN-REGULATION; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; PROPYLENE GLYCOLS; SPHINGOSINE; T-LYMPHOCYTES;

EID: 84865114866     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0454-6     Document Type: Article

References (44)

1. Verselis SJ, Goust JM. CD4? T cell activation in multiple sclerosis. J Neuroimmunol. 1987;14:75-85. (Pubitemid 17219665)
2. Nowell MA, Williams AS, Carty SA, Scheller J, Hayes AJ, Jones GW, Richards PJ, Slinn S, Ernst M, Jenkins BJ, Topley N, Rose- John S, Jones SA. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol. 2009;182:613-22.
3. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 1990;9:1551-60.
4. Ishiyama T, Koike M, Nakamura S, Kakimoto T, Akimoto Y, Tsuruoka N. Interleukin-6 receptor expression in the peripheral B cells of patients with multicentric Castleman's disease. Ann Hematol. 1996;73:179-82. (Pubitemid 26381697)
5. Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H, Mizoguchi A, Mizoguchi E, Mudter J, Galle PR, Bhan A, Autschbach F, Sullivan BM, Szabo SJ, Glimcher LH, Blumberg RS. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med. 2002;195:1129-43. (Pubitemid 34517139)
6. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-44.
7. Sica A. Role of tumour-associated macrophages in cancer-related inflammation. Exp Oncol. 2010;32:153-8.
8. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065-73.
9. Yopp AC, Fu S, Honig SM, Randolph GJ, Ding Y, Krieger NR, Bromberg JS. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol. 2004;173:855-65. (Pubitemid 38924259)
10. Zhi L, Kim P, Thompson BD, Pitsillides C, Bankovich AJ, Yun SH, Lin CP, Cyster JG, Wu MX (2011) FTY720 blocks egress of t cells in part by abrogation of their adhesion on the lymph node sinus. J Immunol 187:2242-2251
11. Suzuki S, Li XK, Enosawa S, Shinomiya T. A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology. 1996;89:518-23. (Pubitemid 26419651)
12. Suzuki S, Li XK, Shinomiya T, Enosawa S, Kakefuda T,Mitsusada M,AmemiyaH,Takahara S,AmariM, Naoe S,HoshinoY,Chiba K. Induction of lymphocyte apoptosis and prolongation of allograft survival by FTY720. Transplant Proc. 1996;28:2049-50. (Pubitemid 26282372)
13. Nagahara Y, Enosawa S, Ikekita M, Suzuki S, Shinomiya T. Evidence that FTY720 induces T cell apoptosis in vivo. Immunopharmacology. 2000;48:75-85. (Pubitemid 30259145)
14. Nagahara Y, Ikekita M, Shinomiya T. T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2. Br J Pharmacol. 2002;137:953-62. (Pubitemid 35440735)
15. FujinoM, LiXK,Guo L,AmanoT, Suzuki S.Activation of caspases and mitochondria in FTY720-mediated apoptosis in human T cell line Jurkat. Int Immunopharmacol. 2001;1:2011-21. (Pubitemid 32835131)
16. Idzko M, Hammad H, van Nimwegen M, Kool M, Muller T, Soullie T, Willart MA, Hijdra D, Hoogsteden HC, Lambrecht BN. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest. 2006;116:2935-44. (Pubitemid 44684478)
17. Nagahara Y, Ikekita M, Shinomiya T. Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J Immunol. 2000;165:3250-9.
18. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296:346-9. (Pubitemid 34303689)
19. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158:1173-82.
20. Sharma S, Mathur AG, Pradhan S, Singh DB, Gupta S. Fingolimod (FTY720): First approved oral therapy for multiple sclerosis. J Pharmacol Pharmacother. 2011;2:49-51.
21. Gorantla S, Liu J, Wang T, Holguin A, Sneller HM, Dou H, Kipnis J, Poluektova L, Gendelman HE. Modulation of innate immunity by copolymer-1 leads to neuroprotection in murine HIV-1 encephalitis. Glia. 2008;56:223-32. (Pubitemid 350292314)
22. Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, Hara M, Sasayama S. FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation. 1999;100:1322-9. (Pubitemid 29440126)
23. Fujii R, Kanai T, Nemoto Y, Makita S, Oshima S, Okamoto R, Tsuchiya K, Totsuka T, Watanabe M. FTY720 suppresses CD4?CD44highCD62L- effector memory T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol. 2006;291:G267-74. (Pubitemid 44024687)
24. Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL, Kappos L. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008;71:1261-7.
25. Wolf AM, Eller K, Zeiser R, Durr C, Gerlach UV, Sixt M, Markut L, Gastl G, Rosenkranz AR, Wolf D. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J Immunol. 2009;183:3751-60.
26. Li Q, Li F. Effects of different dose of FTY720 on lymphocyte cell cycle arrest in cardiac transplantation model of rats. Immunopharmacol Immunotoxicol. 2010;32:680-7.
27. Meno-Tetang GM, Lowe PJ. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol. 2005;96:182-92. (Pubitemid 40387994)
28. Ye Y, Zhang Y, Lu X, Huang X, Zeng X, Lai X, Zeng Y. The anti-inflammatory effect of the SOCC blocker SK&F 96365 on mouse lymphocytes after stimulation by Con A or PMA/ionomycin. Immunobiology. 2011;216:1044-53.
29. Zhao JX, Zeng YY, Liu Y. Fetal alloantigen is responsible for the expansion of the CD4(?)CD25(?) regulatory T cell pool during pregnancy. J Reprod Immunol. 2007;75:71-81. (Pubitemid 47384866)
30. He F, Zeng Y, Wu X, Ji Y, He X, Andrus T, Zhu T, Wang T. Endogenous HIV-1 Vpr-mediated apoptosis and proteome alteration of human T-cell leukemia virus-1 transformed C8166 cells. Apoptosis. 2009;14:1212-26.
31. Fujita T, Inoue K, Yamamoto S, Ikumoto T, Sasaki S, Toyama R, Chiba K, Hoshino Y, Okumoto T. Fungal metabolites. Part A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo). 1994;47:208-15.
32. Adachi K, Chiba K. FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect Medicin Chem. 2008; 1:11-23.
33. Rosen H, Alfonso C, Surh CD, McHeyzer-Williams MG. Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist. Proc Natl Acad Sci USA. 2003;100:10907-12. (Pubitemid 37140126)
34. Ho JW, Man K, Sun CK, Lee TK, Poon RT, Fan ST. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther. 2005;4:1430-8.
35. Zheng T, Meng X, Wang J, Chen X, Yin D, Liang Y, Song X, Pan S, Jiang H, Liu L. PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. J Cell Biochem. 2010;111:218-28.
36. Permpongkosol S, Wang JD, Takahara S, Matsumiya K, Nonomura N, Nishimura K, Tsujimura A, Kongkanand A, Okuyama A. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer. 2002;98:167-72. (Pubitemid 34150797)
37. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9:883-97.
38. Ptachcinski RJ, Carpenter BJ, Burckart GJ, Venkataramanan R, Rosenthal JT. Effect of erythromycin on cyclosporine levels. N Engl J Med. 1985;313:1416-7. (Pubitemid 16211848)
39. Freedman MH, Raff MC. Induction of increased calcium uptake in mouse T lymphocytes by concanavalin A and its modulation by cyclic nucleotides. Nature. 1975;255:378-82.
40. Brewer CF, Brown RD 3rd, Koenig SH. Metal ion binding and conformational transitions in concanavalin A: a structure-function study. J Biomol Struct Dyn. 1983;1:961-97. (Pubitemid 14076139)
41. Segura BJ, Zhang W, Xiao L, Turner D, Cowles RA, Logsdon C, Mulholland MW. Sphingosine-1-phosphate mediates calcium signaling in guinea pig enteroglial cells. J Surg Res. 2004;116:42-54. (Pubitemid 38083284)
42. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G, Billy E, Theuer A, Hla T, Wood J. Antagonism of sphingosine-1- phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 2006;66:221-31. (Pubitemid 43166028)
43. Premenko-Lanier M, Moseley NB, Pruett ST, Romagnoli PA, Altman JD. Transient FTY720 treatment promotes immunemediated clearance of a chronic viral infection. Nature. 2008;454:894-8.
44. Mehling M, Hilbert P, Fritz S, Durovic B, Eichin D, Gasser O, Kuhle J, Klimkait T, Lindberg RL, Kappos L, Hess C. Antigenspecific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol. 2011;69:408-13.